Nexeon MedSystems Inc.

Nexeon MedSystems Inc.

NXNN
Nexeon MedSystems Inc.US flagOther OTC
0.00
USD
- -
- -
78,625.00Market Cap
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
- -
1.11
1.86
4.99
Basic EPS, GAAP
- -
-0.6
-1.23
-0.84
Free Cash Flow per Basic Share
- -
0.09
-1.79
0.29
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
-1.15
-2.09
-3.46
Tangible Book Value per Share
- -
1.2
0.64
-0.35
Basic Weighted Avg Shares
- -
1
2
2
Sales/Revenue/Turnover
- -
1
3
10
Operating Margin (%)
- -
-42.43
-184.41
-57.69
Depreciation Expense
- -
1
1
1
Net Income, GAAP
- -
-1
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
- -
-53.68
-65.93
-16.84
Working Capital
- -
2
1
-2
LT Debt
- -
- -
3
2
Total Equity
- -
11
12
9
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
475.64
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Mar'18
Jun'18
Sep'18
ST Debt
1
1
2
LT Borrowings
3
3
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
23
39
16

Working Capital

FRC

in mil. unless spec.
Mar'18
Jun'18
Sep'18
Total Current Assets
5
5
5
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
2
2
2
Inventories
2
2
2
Total Current Liabilities
5
6
7
Payables & Accruals
4
4
5
ST Debt
1
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
4.83%
Free Cash Flow
- -
- -
-2,855.03%
Net Income, GAAP
- -
- -
171.37%
Sales/Revenue/Turnover
- -
- -
120.94%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
1
2017
- -
- -
1
2
3
2018
3
3
2
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.1
-0.19
-0.43
- -
-0.6
2017
-1.25
-0.81
-0.22
- -
-1.23
2018
-0.48
-0.37
-0.71
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
William Rosellini
Full Time Employees
62
Sector
Healthcare
Industry
Medical - Devices
Address
1910 Pacific Avenue Dallas TX United States of America 75201
IPO Date
Sep 27, 2017
Business
Nexeon MedSystems Inc. (NXNN) develops, manufactures and commercializes neurostimulation technology platforms for treating neurological disorders through electrical stimulation of neural tissues; its core offerings include deep brain stimulation systems such as the Viant for Parkinson's disease in the United States and for Parkinson's disease, essential tremor and dystonia in Europe, alongside technologies spanning peripheral nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation and advanced depth electrodes for epilepsy monitoring and neural interfaces. Founded in 2005 and headquartered in Dallas, Texas, with manufacturing and clinical subsidiaries in Belgium, the company operates globally in the bioelectronics and medtech sectors, targeting patients with debilitating conditions like migraines, cardiovascular disease and sepsis via implantable devices and IoT-enabled remote management software. Recent developments encompass a November 2024 strategic partnership with Cochlear to co-develop integrated neural interface devices including advanced depth electrode configurations, alongside earlier acquisitions of neuromodulation intellectual property from Neurotek Medical in 2016 and Medi-Line in 2017 to bolster electrode design and OEM manufacturing capabilities.

Company News

APIChatGPT
  • QT Imaging (NASDAQ:QTI) vs. Nexeon Medsystems (OTCMKTS:NXNN) Financial Review

  • Head-To-Head Review: QT Imaging (NASDAQ:QTI) and Nexeon Medsystems (OTCMKTS:NXNN)

  • QT Imaging (NASDAQ:QTI) and Nexeon Medsystems (OTCMKTS:NXNN) Critical Survey

  • Critical Comparison: QT Imaging (NASDAQ:QTI) vs. Nexeon Medsystems (OTCMKTS:NXNN)